On September 13, 2017, the world’s first multidisciplinary Open Access journal, PLOS ONE published a study “Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China” from The George Institute, China, which demonstrated that the School-EduSalt intervention program for salt reduction is of low cost and highly cost-effective.
On 4th August, China's Department of Maternal and Child Health of National Health and Family Planning Commission (Department of MCH, NHFPC) and United Nations Population Fund China Office (UNFPA China) held the symposium on "Women’s health through life course and empowerment" successfully in Beijing, which was also jointly co-organized by the National Office for Maternal and Child Health Surveillance and The George Institute, China (TGI China).
On July 30, 2017, the 'Salt Substitute and Stroke Study' (SSaSS) 2017 annual meeting was held in Xiongan New District, Baoding, Hebei Province. More than 40 delegates attended the meeting, reported project progress and shared experiences. Participants included Principal Investigators from China and Australia, local Project Investigators, Project Coordinators, and government officials from the local Health and Family Planning Committee and Centers for Disease Control.
Researchers from The George Institute for Global Health have been awarded funds from UK’s National Institute for Health Research (NIHR) to address the health challenge of stroke care in India and tackle salt consumption in China.
As one of the largest basal insulin research projects in China, the Observational Registry for Basal Insulin Treatment (ORBIT) project was initiated by the Chinese Diabetes Society (CDS), conducted and managed by The George Institute, China and supported by Sanofi China. ORBIT was launched in 2011 and has successfully published research findings this year after the positive participation of 209 secondary and tertiary hospitals nationwide, hundreds of doctors and follow-up of nearly 20,000 patients with type 2 diabetes for 6 months.